Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
- PMID: 10430112
- DOI: 10.1016/S0009-9236(99)70056-1
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
Abstract
Purpose: To compare the renal hemodynamic and tubular effects of celecoxib, a selective inhibitor of cyclooxygenase-2 (COX-2) to those of naproxen, a nonselective inhibitor of cyclooxygenases in salt-depleted subjects.
Methods and subjects: Forty subjects were randomized into four parallel groups to receive 200 mg celecoxib twice a day, 400 mg celecoxib twice a day, 500 mg naproxen twice a day, or a placebo for 7 days according to a double-blind study design. Blood pressure, renal hemodynamics, and urinary water and electrolyte excretion were measured before and for 3 hours after drug intake on days 1 and 7.
Results: Celecoxib had no effect on systemic blood pressure, but short-term transient decreases in renal blood flow and glomerular filtration rate were found with the highest dose of 400 mg on day 1. On the first day, both celecoxib and naproxen decreased urine output (P < .05) and sodium, lithium, and potassium excretion (P < .01). On day 7, similar effects on water and sodium excretion were observed. During repeated administration, a significant sodium retention occurred during the first 3 days.
Conclusion: In salt-depleted subjects, selective inhibition of COX-2 causes sodium and potassium retention. This suggests that an increased selectivity for COX-2 does not spare the kidney, at least during salt depletion.
Similar articles
-
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.Clin Pharmacol Ther. 2002 Jul;72(1):50-61. doi: 10.1067/mcp.2002.126182. Clin Pharmacol Ther. 2002. PMID: 12152004 Clinical Trial.
-
Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.J Clin Pharmacol. 2002 Sep;42(9):985-94. J Clin Pharmacol. 2002. PMID: 12211224 Clinical Trial.
-
Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake.Clin Pharmacol Ther. 2005 May;77(5):437-50. doi: 10.1016/j.clpt.2005.01.011. Clin Pharmacol Ther. 2005. PMID: 15900289 Clinical Trial.
-
COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.J Hypertens Suppl. 2002 Sep;20(6):S31-5. J Hypertens Suppl. 2002. PMID: 12683425 Review.
-
Outcome of specific COX-2 inhibition in rheumatoid arthritis.J Rheumatol Suppl. 1997 Jul;49:9-14. J Rheumatol Suppl. 1997. PMID: 9249645 Review.
Cited by
-
Nonsteroidal Anti-Inflammatory Drugs and the Kidney.Pharmaceuticals (Basel). 2010 Jul 21;3(7):2291-2321. doi: 10.3390/ph3072291. Pharmaceuticals (Basel). 2010. PMID: 27713354 Free PMC article. Review.
-
Renal failure associated with the use of celecoxib and rofecoxib.Drug Saf. 2002;25(7):537-44. doi: 10.2165/00002018-200225070-00007. Drug Saf. 2002. PMID: 12093311 Review.
-
Comparative Effects of Metamizole (Dipyrone) and Naproxen on Renal Function and Prostacyclin Synthesis in Salt-Depleted Healthy Subjects - A Randomized Controlled Parallel Group Study.Front Pharmacol. 2021 Sep 7;12:620635. doi: 10.3389/fphar.2021.620635. eCollection 2021. Front Pharmacol. 2021. PMID: 34557087 Free PMC article.
-
Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis.Sci Rep. 2025 Jul 1;15(1):21066. doi: 10.1038/s41598-025-07146-8. Sci Rep. 2025. PMID: 40596533 Free PMC article.
-
Nonsteroidal anti-inflammatory drugs and heart failure.Drugs. 2003;63(6):525-34. doi: 10.2165/00003495-200363060-00001. Drugs. 2003. PMID: 12656651 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials